Application N

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10708315
Filing Date	2004-02-24
First Named Inventor	David E. Mekas
Art Unit	1772
Examiner Name	Alicia Ann Chevalier
Attorney Docket Numb	m MASL-31

				U.S.	PATENTS	Remove	
Examiner Initial*	Cite No			Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	7051438	B2	2006-05-30	O'Brien et al.		
	2	7045206	B1	2006-05-16	Granata et al.		
	3	7018702	B2	2006-03-28	Hacke		
	4	6857688	B2	2005-02-22	Morrison et al.		
	5	6827799	B2	2004-12-07	Zimmer et al.		
	6	6616216	B2	2003-09-09	Furuyama et al.		
	7	6615546	B2	2003-09-09	Furuyama et al.		
If you wis	h to ac	dd additional U.S. Pate			lease click the Add button.	Add	
U.S.PATENT APPLICATION PUBLICATIONS Remove							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708315
iling Date		2004-02-24
irst Named Inventor David		E. Mekas
Art Unit		1772
Examiner Name Alicia		Ann Chevalier
Attorney Docket Number		MASL-31

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	entee or Applicant iment	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1									
If you wisl	h to a	ı dd additional U.S. Publi	shed Ap	plication	citatio	ı n information p	please click the Ad	d butto	n. Add	
				FORE	GN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5
	1									
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	buttor	Add	_
			NON	1-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andior country where published.					Тв				
1 US Petent and Trademark Office, Office Action in Application No. 10/994,407, August 14, 2006, 46 pages.										

Examiner Signature Date Considered Date Considered Examiner Signature Date Considered Examiner Signature Date Considered Date Considered Examiner Signature Date Considered, whether on catalotic is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

See Kinz Codes of USPTO Patient Documents at year USPTO_CODE or MPEP 901.6. If Earls office that assed the document, by the holefar code (WIPO Standard ST.3). Sort Justinese plants documents, by an advanced by any of the Temporar must procecible be serial number of the plants of the Temporar must proceed be serial number of the plants of countered. If kind of countered by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. If Applicant is to place a check mark here if English language the installation is attacked.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708315
Filing Date		2004-02-24
First Named Inventor David		E. Mekas
Art Unit		1772
Examiner Name Alicia		Ann Chevalier
Attorney Docket Number		MASL-31

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
7	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David W. Dorton/	Date (YYYY-MM-DD)	2006-08-25					
Name/Print	David W. Dorton	Registration Number	51625					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenant Afford, U.S. Department of Commence, P. D. 6th 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.4450

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.